Adocia Unveils New Peptide Modification Platform
Biopharmaceutical company Adocia announces the filing of a patent for its AdoXLong platform, aimed at extending the action of peptides to one month.
Company Overview
Adocia, listed on Euronext Paris (ISIN: FR0011184241), focuses on developing therapeutic solutions for diabetes and obesity. Based in Lyon, the company employs about 80 people and holds more than 25 patent families.
Introduction of the AdoXLong Platform
Adocia's new AdoXLong platform, supported by a patent application, aims to extend the action of peptides, such as semaglutide, over a period of one month. It uses a biocompatible polymer chemically bonded to the peptides, allowing subcutaneous administration with fine needles. Additionally, the company's BioChaperone technology is currently undergoing two feasibility studies in collaboration with unnamed pharmaceutical companies.
Strategic Implications
The AdoXLong platform addresses the need for improved therapeutic persistence in the treatment of diabetes and obesity, while optimizing production capacity. By applying this technology to various peptides, Adocia hopes to strengthen its intellectual property until 2046. Furthermore, the BioChaperone technology continues to be explored for potential obesity treatments.
